International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

International System for Human Cytogenetic Nomenclature

National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619

Myelodysplastic syndromes: a scoring system with prognostic significance

Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406

The 5q− anomaly

BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma

Gökgöz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8 · Cited by 125

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Westers, T. M., Alhan, C., Chamuleau, M. E. D., van der Vorst, M. J. D. L., Eeltink, C., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2009) · Blood · doi:10.1182/blood-2009-08-239749 · Cited by 92

Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome

Hou, H., Tsai, C., Lin, C., Chou, W., Kuo, Y., Liu, C., Tseng, M., Peng, Y., Liu, M.-C., Liu, C., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0074-7 · Cited by 95

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

Valencia, A., Masala, E., Rossi, A., Martino, A., Sanna, A., Buchi, F., Canzian, F., Cilloni, D., Gaidano, V., Voso, M. T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.330 · Cited by 94

Focus on myeloproliferative diseases and myelodysplastic syndromes

Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 92

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

Tam, C. S. L., Abruzzo, L. V., Lin, K. I., Cortes, J. E., Lynn, A., Keating, M. J., Thomas, D. A., Pierce, S. A., Kantarjian, H. M., & Verstovšek, S. (2009) · Blood · doi:10.1182/blood-2008-09-178541 · Cited by 92

Evolution Of Clonal Cytogenetic Abnormalities in Aplastic Anemia

Maciejewski, J. P., & Selleri, C. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001602363 · Cited by 92

Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype

Rigolin, G. M., Bigoni, R., Milani, R., Cavazzini, F., Roberti, M. G., Bardi, A., Agostini, P., Porta, M. G. D., Tieghi, A., Piva, N., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402293 · Cited by 92

Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment

Camaschella, C. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.07.001 · Cited by 92

Validation of the revised international prognostic scoring system ( IPSS ‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS ( EUMDS ) registry

de Swart, L., Smith, A. G., Johnston, W. T., Haase, D. T., Droste, J., Fenaux, P., Symeonidis, A. S., Sanz, G. F., Hellström‐Lindberg, E., Čermák, J., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13450 · Cited by 94

Hematopoiesis-related microRNA expression in myelodysplastic syndromes

Pons, A., Nomdedeu, B., Navarro, A., Gayà, A., Gel, B., Díaz, T., Valera, S., Rozman, M., Belkaid, M., Montserrat, E., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903147645 · Cited by 91

7 Molecular genetics and cytogenetics of myeloproliferative disorders

Bench, A. J., Nacheva, E. P., Champion, K. M., & Green, A. R. (1998) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(98)80041-3 · Cited by 91

Molecular Pathophysiology of Myelodysplastic Syndromes

Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

Wang, R., Gross, C. P., Halene, S., & Ma, X. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.005 · Cited by 90

Azacytidine (Vidaza�) in the treatment of myelodysplastic syndromes

Raj, K. K., & Mufti, G. J. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.4.377 · Cited by 90

Myelodysplasia‐associated autoimmunity: clinical and pathophysiologic concepts

Voulgarelis, M., Giannouli, S., Ritis, K., & Tzioufas, A. G. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01417.x · Cited by 90

188Re or 90Y‐labelled anti‐CD66 antibody as part of a dose‐reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study

Ringhoffer, M., Blumstein, N. M., Neumaier, B., Glatting, G., von Harsdorf, S., Buchmann, I., Wiesneth, M., Kotzerke, J., Zenz, T., Buck, A. K., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05663.x · Cited by 90

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen

Deeg, H. J., Storer, B. E., Boeckh, M., Martin, P. J., McCune, J. S., Myerson, D., Heimfeld, S., Flowers, M. E. D., Anasetti, C., Doney, K., et al. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.12.036 · Cited by 90

Outcome of Donor Lymphocyte Infusion after T Cell–depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes

Krishnamurthy, P., Potter, V. T., Barber, L. D., Kulasekararaj, A. G., Lim, Z. Y., Pearce, R., de Lavallade, H., Kenyon, M., Ireland, R. M., Marsh, J. C. W., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.12.013 · Cited by 90

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

Heinrichs, S., Kulkarni, R. V., Bueso‐Ramos, C. E., Levine, R. L., Loh, M. L., Li, C., Neuberg, D. S., Kornblau, S. M., Issa, J. J., Gilliland, D. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.82 · Cited by 90

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT

Martino, R., de Wreede, L. C., Fiocco, M. F., van Biezen, A., Borne, P. A. V. D., Hamladji, R.-M., Volin, L., Bornhäuser, M., Robin, M., Rocha, V., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.236 · Cited by 89

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Bazinet, A., Darbaniyan, F., Jabbour, E. J., Bravo, G. M., Ohanian, M. N., Chien, K. S., Kadia, T. M., Takahashi, K., Masárová, L., Short, N. J., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00216-2 · Cited by 89

Myelodysplastic syndromes

Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Issa, J. J., Estey, E. H., Keating, M. J., & Freireich, E. J. (2008) · Cancer · doi:10.1002/cncr.23655 · Cited by 90

The cytogenetics of myelodysplastic syndromes

Olney, H. J., & Beau, M. M. L. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0151 · Cited by 89

How I treat patients with myelodysplastic syndromes

Stone, R. M. (2009) · Blood · doi:10.1182/blood-2008-09-038935 · Cited by 90

Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.

Vallespı́, T., Imbert, M., Mecucci, C., Preudhomme, C., & Fenaux, P. (1998) · PubMed · Cited by 89

Myelodysplasic syndromes: A comprehensive review

Catenacci, D. V. T., & Schiller, G. J. (2005) · Blood Reviews · doi:10.1016/j.blre.2005.01.004 · Cited by 89

Myelodysplastic Syndromes

Steensma, D. P. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.001 · Cited by 91

Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia

Witherspoon, R. P., Deeg, H. J., Storer, B. E., Anasetti, C., Storb, R. F., & Appelbaum, F. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2134 · Cited by 88

Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based Statistics

Aul, C., Giagounidis, A. A. N., & Germing, U. (2001) · International Journal of Hematology · doi:10.1007/bf02994001 · Cited by 88

International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome

Kita‐Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H., & Taniwaki, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03073.x · Cited by 88

The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

van den Bosch, J., Lübbert, M., Verhoef, G. E. G., & Wijermans, P. (2004) · Leukemia Research · doi:10.1016/j.leukres.2003.11.016 · Cited by 88

Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution

BERNASCONI, P. P., Klersy, C., Boni, M., Cavigliano, P. M., Calatroni, S., Giardini, I., Rocca, B., Zappatore, R., Caresana, M., Quarna, J., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403806 · Cited by 88

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

Balleari, E., Rossi, E., Clavio, M., Congiu, A. M., Gobbi, M., Grosso, M., Secondo, V., Spriano, M., Timitilli, S., & Ghio, R. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0044-6 · Cited by 88

Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome

Allampallam, K., Shetty, V. T., Mundle, S. D., Dutt, D., Kravitz, H. M., Reddy, P. L., Alvi, S., Galili, N., Saberwal, G. S., Anthwal, S., et al. (2002) · International Journal of Hematology · doi:10.1007/bf02982044 · Cited by 88

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

Aivado, M. A., Spentzos, D., Germing, U., Alterovitz, G., Meng, X.-Y., Grall, F. T., Giagounidis, A. A. N., Klement, G. L., Steidl, U. U., Otu, H. H., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610330104 · Cited by 88

The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation

Follo, M. Y., Mongiorgi, S., Bosi, C., Cappellini, A., Finelli, C., Chiarini, F., Papa, V., Libra, M., Martinelli, G., Cocco, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4409 · Cited by 87

Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes

Iwanaga, M., Furukawa, K., Amenomori, T., Mori, H., Nakamura, H., Fuchigami, K., Kamihira, S., Nakakuma, H., & Tomonaga, M. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00794.x · Cited by 87

Current therapy of myelodysplastic syndromes

Zeidan, A. M., Linhares, Y. P. L., & Gore, S. D. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.003 · Cited by 87

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

Cluzeau, T., Robert, G., Mounier, N., Karsenti, J. M., Dufies, M., Puissant, A., Jacquel, A., Renneville, A., Preudhomme, C., Cassuto, J. P., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.481 · Cited by 93

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

Andersson, B. S., Thall, P. F., Valdez, B. C., Milton, D. R., Alatrash, G., Chen, J., Gulbis, A. M., Chu, D. T., Martinez, C., Parmar, S., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.322 · Cited by 86

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Efficace, F., Gaïdano, G., Breccia, M., Voso, M. T., Cottone, F., Angelucci, E., Caocci, G., Stauder, R., Selleslag, D., Sprangers, M. A. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00206-5 · Cited by 86

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

Robin, M., Porcher, R., Adès, L., Raffoux, E., Michallet, M., François, S., Cahn, J.-Y. Y., Delmer, A. J., Wattel, E., Vigouroux, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.37 · Cited by 86

Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients

Govindaraj, C., Tan, P. T., Walker, P., Wei, A. H., Spencer, A. G., & Plebanski, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1576 · Cited by 86

Prognostic Factors of Hepatosplenic T-cell Lymphoma

Yabe, M., Medeiros, L. J., Tang, G., Wang, S. A., Ahmed, S., Nieto, Y. L., Hu, S., Bhagat, G., Oki, Y., Patel, K. P., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000614 · Cited by 86

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations

Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 89

Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype

Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Knudson, R. A., Dyke, D. L. V., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.258 · Cited by 85

Therapy with azanucleosides for myelodysplastic syndromes

Quintás‐Cardama, A., Santos, F. P. S., & Garcia‐Manero, G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.87 · Cited by 85

Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow

Figueroa, E. F., Varma, S., Montgomery, K. D., Greenberg, P. L., & Gratzinger, D. A. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.93 · Cited by 86

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

Zeidan, A. M., Sekeres, M. A., Garcia‐Manero, G., Steensma, D. P., Zell, K., Barnard, J., Ali, N. E. A., Zimmerman, C., Roboz, G. J., Dezern, A. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.283 · Cited by 85

Exposure to myelotoxic agents and myelodysplasia: case–control study and correlation with clinicobiological findings

Rigolin, G. M., Cuneo, A., Roberti, M. G., Bardi, A., Bigoni, R., Piva, N., Minotto, C., Agostini, P., Angeli, C. D., SENNO, L. D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00963.x · Cited by 85

Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia

Schroeder, T. A., Wegener, N., Lauseker, M., Rautenberg, C., Nachtkamp, K., Schuler, E., Kondakci, M., Haas, R. R., Germing, U., & Kobbe, G. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.03.011 · Cited by 83

Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome

Olíva, E. N., Dimitrov, B. D., Benedetto, F. A., D’Angelo, A., & Nobile, F. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.03.004 · Cited by 84

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

Rogers, H. J., Vardiman, J. W., Anastasi, J., Raca, G., Savage, N. M., Cherry, A. M., Arber, D. A., Moore, E. M., Morrissette, J. J. D., Bagg, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096420 · Cited by 84

Prognostic evaluation of the microvascular network in myelodysplastic syndromes

Korkolopoulou, P., Apostolidou, E., Pavlopoulos, P., Kavantzas, N., Vyniou, N., Thymara, I., Terpos, E., Patsouris, E., Yataganas, X., & Davaris, P. (2001) · Leukemia · doi:10.1038/sj.leu.2402220 · Cited by 84

IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution

Lin, C., Hou, H., Chou, W., Kuo, Y., Liu, C., Chen, C., Lai, Y.-J., Tseng, M., Huang, C., Chiang, Y., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23596 · Cited by 85

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review

Oliansky, D. M., Antin, J. H., Bennett, J. M., Deeg, H. J., Engelhardt, C., Heptinstall, K. V., Lima, M. J. G. D., Gore, S. D., Potts, R. G., Silverman, L. R., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.12.003 · Cited by 84

Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification

Font, P., Loscertales, J., Benavente, C., Bermejo, A., Callejas, M., Garcia-Alonso, L., Garcia-Marcilla, A., Gil, S., López‐Rubio, M., Martin, E., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1565-4 · Cited by 83

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

Chee, C. E., Steensma, D. P., Wu, W., Hanson, C. A., & Tefferi, A. (2008) · American Journal of Hematology · doi:10.1002/ajh.21192 · Cited by 83

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

Ustwani, O. A., Ford, L. A., Sait, S. N. J., Block, A. M. W., Barcos, M. P., Vigil, C. E., Griffiths, E. A., Thompson, J. E., Wang, E. S., Ambrus, J. L., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.04.007 · Cited by 84

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells

Wei, Y., Chen, R., Dimicoli, S., Bueso‐Ramos, C. E., Neuberg, D. S., Pierce, S. A., Wang, H., Yang, H., Jia, Y., Zheng, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.91 · Cited by 84

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

Ruutu, T., Volin, L., Beelen, D. W., Trenschel, R., Finke, J., Schnitzler, M., Hołowiecki, J., Giebel, S., Markiewicz, M., Uharek, L., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.043810 · Cited by 83

Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology

Pellagatti, A., Esoof, N., Watkins, F., Langford, C. F., Vetrie, D. L. P., Campbell, L. J., Fidler, C., Cavenagh, J. D., Eagleton, H., Gordon, P., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04958.x · Cited by 83

Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies

Greenberg, P. L. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0010 · Cited by 83

Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics

Pfeilstöcker, M., Reisner, R., Nösslinger, T., Grüner, H., Nowotny, H., Tüchler, H., Schlögl, E., Pittermann, E., & Heinz, R. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01559.x · Cited by 83

Myelodysplastic syndromes: 2012 update on diagnosis, risk‐stratification, and management

Garcia‐Manero, G. (2012) · American Journal of Hematology · doi:10.1002/ajh.23264 · Cited by 82

Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia

Galm, O., Wilop, S., Lüders, C., Jost, E., Gehbauer, G., Herman, J. G., & Osieka, R. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0005-0 · Cited by 82

Gene expression and risk of leukemic transformation in myelodysplasia

Shiozawa, Y., Malcovati, L., Gallì, A., Pellagatti, A., Karimi, M., Sato‐Otsubo, A., Sato, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2017) · Blood · doi:10.1182/blood-2017-05-783050 · Cited by 82

Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens

Parker, J. E., Shafi, T., Pagliuca, A., Mijović, A., Devereux, S., Potter, M. N., Prentice, H. G., Garg, M. K., Yin, J. A. L., Byrne, J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03796.x · Cited by 82

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age

Koreth, J., Aldridge, J., Kim, H. T., Alyea, E. P., Cutler, C. S., Armand, P. A., Ritz, J., Antin, J. H., Soiffer, R. J., & Ho, V. T. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.12.537 · Cited by 81

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

Platzbecker, U., Wong, R. S. M., Verma, A. K., Abboud, C. N., Araujo, S., Chiou, T.-J., Feigert, J. M., Yeh, S., Götze, K. S. S., Gorin, N. C., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00149-0 · Cited by 81

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis ( RARS ‐ T ): 2017 update on diagnosis, risk‐stratification, and management

Patnaik, M. M., & Tefferi, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24637 · Cited by 81

Transfusion independence in patients with myelodysplastic syndromes

Balducci, L. (2006) · Cancer · doi:10.1002/cncr.21860 · Cited by 81

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

Font, P., Loscertales, J., Soto, C., Ricard, P., Muñoz‐Novas, C., Martín‐Clavero, E., López-Rubio, M., Garcia-Alonso, L., Callejas, M., Bermejo, A., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2252-4 · Cited by 81

Myelodysplastic syndrome and associated skin lesions: a review of the literature

Avivi, I. M., Rosenbaum, H., Levy, Y., & Rowe, J. M. (1999) · Leukemia Research · doi:10.1016/s0145-2126(98)00161-1 · Cited by 81

Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Pedersen-Bjergaard, J., Andersen, M. T., & Andersen, M. K. (2007) · Hematology · doi:10.1182/asheducation-2007.1.392 · Cited by 81

Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia

Ayas, M. F., Saber, W., Davies, S. M., Harris, R. E., Hale, G. A., Socié, G., Le‐Rademacher, J. G., Thakar, M. S., Deeg, H. J., Al-Seraihy, A. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9719 · Cited by 82

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

Greenberg, P. L., Garcia‐Manero, G., Moore, M., Damon, L. E., Roboz, G. J., Hu, K., Yang, A. S., & Franklin, J. L. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.713477 · Cited by 81

Smoking and Myelodysplastic Syndromes

Björk, J., Albin, M. C., Mauritzson, N., Strömberg, U., Johansson, B., & Hagmar, L. (2000) · Epidemiology · doi:10.1097/00001648-200005000-00010 · Cited by 81

Increasing incidence of myelodysplastic syndromes: Real or fictitious?

Aul, C., Germing, U., Gattermann, N., & Minning, H. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00089-1 · Cited by 81

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

on behalf of the International Working Group on MDS with del(5q), Kuendgen, A., Lauseker, M., List, A. F., Fenaux, P., Giagounidis, A. A. N., Brandenburg, N. A., Backstrom, J. T., Glasmacher, A., Hasford, J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.369 · Cited by 81

U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Qian, J., Yao, D., Lin, J., Qian, W., Wang, C.-Z., Chai, H., Yang, J. C., Li, Y., Deng, Z., Ma, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045760 · Cited by 78

Myelodysplastic Syndrome Updated

Hasserjian, R. P. (2018) · Pathobiology · doi:10.1159/000489702 · Cited by 81

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

Göhring, G., Giagounidis, A. A. N., Büsche, G., Kreipe, H. H., Zimmermann, M., Hellström‐Lindberg, E., Aul, C., & Schlegelberger, B. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0846-z · Cited by 80

Telomere shortening and chromosomal instability in myelodysplastic syndromes

Lange, K., Holm, L., Nielsen, K. V., Hahn, A., Hofmann, W. A., Kreipe, H. H., Schlegelberger, B., & Göhring, G. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20737 · Cited by 79

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

Park, S., Labopin, M., Yakoub‐Agha, I., Delaunay, J., Dhédin, N., Deconinck, É., Michallet, M., Robin, M., de Revel, T., Bernard, M., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12073 · Cited by 80

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

Santini, V., Allione, B., Zini, G., Gioia, D. M., Lunghi, M., Poloni, A., Cilloni, D., Sanna, A., Masiera, E., Ceccarelli, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.186 · Cited by 80

Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome

Ooi, J., Iseki, T., Takahashi, S., Tomonari, A., Ishii, K., Takasugi, K., Shimohakamada, Y., Ohno, N., Uchimaru, K., Nagamura, F., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3917 · Cited by 80

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Kuendgen, A., Nomdedéu, M., Tuechler, H., Garcia‐Manero, G., Komrokji, R. S., Sekeres, M. A., Porta, M. G. D., Cazzola, M., Dezern, A. E., Roboz, G. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0917-7 · Cited by 83

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Garcia‐Manero, G., Santini, V., Almeida, A. M., Platzbecker, U., Jonasova, A. T., Silverman, L. R., Falantes, J. F., Reda, G., Buccisano, F., Fenaux, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02619 · Cited by 79

Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study

Cherry, A. M., Brockman, S. R., Paternoster, S. F., Hicks, G. A., Neuberg, D. S., Higgins, R. R., Bennett, J. M., Greenberg, P. L., Miller, K. B., Tallman, M. S., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00104-8 · Cited by 79

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini, V., Schemenau, J., Levis, A., Balleari, E., Sapena, R., Adès, L., Guerci‐Bresler, A., Beyne‐Rauzy, O., Gourin, M.-P., Chèze, S., et al. (2013) · Blood · doi:10.1182/blood-2013-07-512442 · Cited by 79

Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy

Leitch, H. A. (2007) · Leukemia Research · doi:10.1016/s0145-2126(07)70460-5 · Cited by 79

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

Lee, Y., Kim, I., Yoon, S., Park, S., Cheong, J., Min, Y. H., Lee, J., Bang, S., Yi, H. G., Kim, C. S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12256 · Cited by 79

Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure

West, R. R., Stafford, D. A., White, A. D., Bowen, D., & Padua, R. A. (2000) · Blood · doi:10.1182/blood.v95.6.2093 · Cited by 79

Treating Leukemia in the Time of COVID-19

Paul, S., Rausch, C. R., Jain, N., Kadia, T. M., Ravandi, F., Dinardo, C. D., Welch, M. A., Dabaja, B. S., Daver, N. G., Garcia‐Manero, G., et al. (2020) · Acta Haematologica · doi:10.1159/000508199 · Cited by 77

Phase 2, single‐arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

Gabrilove, J. L., PAQUETTE, R. L., Lyons, R. M., Mushtaq, C., Sekeres, M. A., Tomita, D. K., & Dreiling, L. K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07181.x · Cited by 78

Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4+ subset and oligoclonal in the CD8+ subset

Fozza, C., Contini, S., Galleu, A., Simula, M. P., Virdis, P., Bonfigli, S., & Longinotti, M. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.009 · Cited by 78

Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study

Neukirchen, J., Lauseker, M., Blum, S., Giagounidis, A. A. N., Lübbert, M., Martino, S., Siragusa, S. M., Schlenk, R. F., Platzbecker, U., Hofmann, W., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.10.013 · Cited by 78

Risk factors and their relationship to prognosis in myelodysplastic syndromes

Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00040-x · Cited by 19

Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories

Falantes, J. F., Calderón, C., Márquez-Malaver, F. J., Alonso, D., Noya, A. M., Carrillo, E., Martino, M. L., Montero, I., González, J., Parody, R., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.013 · Cited by 19

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688

Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes

Steidl, C., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kuendgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., et al. (2007) · Clinical Leukemia · doi:10.3816/clk.2007.n.029 · Cited by 8

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A. A. N., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 159